DB Ashbourne Limited has been acquired by Ethypharm S.A
The shareholder of DB Ashbourne Limited (DBA) has sold the company to Ethypharm S.A. for an undisclosed consideration.
DBA currently markets and supplies a range of prescription-only medicines to the UK market, generating significant savings for the National Health Service (NHS) and has an exciting pipeline of products in development which will be supplemented with a wide range of additional products from the Ethypharm pipeline.
Ethypharm S.A. is a France-based company engaged in developing, manufacturing and licensing pharmaceutical products. Through the acquisition of DBA, Ethypharm continues to implement its strategy to develop a direct commercial presence in key territories in Europe to market central nervous system products, with a particular focus on pain and innovative treatments for addictions. DBA provides a pivotal platform to generate revenues in the important UK market and this acquisition, along with the deployment of its own commercial operations in France and Germany, will generate a large turnover.
“I am delighted to welcome the DBA team to the Ethypharm group. The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic and DBA offers a great platform to launch products from our own pipeline,” declared Hugues Lecat, CEO of Ethypharm.
Oaklins Cavendish, based in the UK, advised the seller in this transaction.
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
Valmiermuižas Alus has been acquired by Cēsu Alus
Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreArmira has signed an agreement to acquire a majority stake in Viabus
Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.
Learn more